Product image of Minkonti (Mirabegron) supplied by GNH India

Minkonti

Active Ingredient:
Mirabegron
Origin:
EU

Minkonti (Mirabegron)

Mirabegron, the active ingredient in Minkonti, is a β3 adrenergic receptor agonist presented as an oral tablet for systemic use. It is indicated for the treatment of overactive bladder symptoms, including urinary urgency, frequency, and urge incontinence, in adult patients. By targeting detrusor muscle receptors, it helps increase bladder capacity and reduce involuntary contractions.

GNH India supplies Minkonti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Minkonti (mirabegron) is used to manage disorders of bladder storage by modulating β3‑adrenergic receptors.

  • Overactive bladder: reduces urgency episodes, urinary frequency and improves overall bladder control.
  • Urge urinary incontinence: decreases the number of incontinence episodes by enhancing bladder capacity.
  • Neurogenic detrusor overactivity: improves storage function in patients with neurologic conditions affecting bladder control.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors located in the detrusor smooth muscle of the bladder. Activation leads to relaxation of the detrusor muscle during the storage phase, thereby increasing bladder capacity and reducing involuntary contractions that cause urgency and incontinence.

Side Effects

Minkonti may cause a range of adverse reactions. Patients should be aware of both common and less frequent but serious events.

Common Side Effects

  • Hypertension: increase in blood pressure, often mild to moderate.
  • Headache: transient, may resolve without intervention.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Urinary retention: difficulty initiating or maintaining urine flow.
  • Constipation: reduced bowel movements.
  • Dry mouth: decreased salivation.

Serious or Rare Side Effects

  • Severe hypertension: marked elevation requiring medical attention.
  • Angioedema: swelling of face, lips, tongue or throat.
  • Acute urinary retention leading to obstruction.
  • QT interval prolongation: rare cardiac conduction abnormality.
  • Anaphylactic reaction: severe allergic response requiring emergency care.

Precautions & Warnings

Before initiating therapy with Minkonti, clinicians should consider several safety aspects.

  • Blood pressure monitoring: check baseline and periodically during treatment.
  • Urinary retention assessment: evaluate for pre‑existing retention or obstruction.
  • Renal and hepatic function: adjust use in patients with significant impairment.
  • Uncontrolled hypertension: avoid use in patients with markedly elevated blood pressure.
  • Concomitant QT‑prolonging drugs: monitor ECG if combined with other agents that affect cardiac repolarization.
  • Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Minkonti can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirabegron plasma concentrations.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce mirabegron effectiveness.
  • Antihypertensive agents: additive blood pressure effects may require dose adjustments.

Moderate Interactions (Monitor Closely)

  • Anticholinergic drugs: may diminish therapeutic benefit on bladder symptoms.
  • Diuretics: increased risk of urinary retention.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential for heightened blood pressure response.

Frequently Asked Questions

Minkonti contains mirabegron, a prescription medication indicated for the treatment of overactive bladder in adults. It helps relieve symptoms such as urinary urgency, increased frequency, and urge urinary incontinence by relaxing the bladder’s detrusor muscle and increasing storage capacity.

Mirabegron selectively stimulates β3‑adrenergic receptors on the detrusor smooth muscle of the bladder. This activation causes the muscle to relax during the filling phase, which expands bladder capacity and reduces involuntary contractions that trigger urgency and incontinence.

The dosage of Minkonti is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any relevant comorbidities. The prescriber will select the appropriate strength and dosing schedule according to approved guidelines.

Safety of mirabegron in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Minkonti, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative for overactive bladder is the antimuscarinic class (e.g., oxybutynin). Antimuscarinics block muscarinic receptors and often cause dry mouth and constipation, whereas mirabegron works via β3‑adrenergic activation and typically has a different side‑effect profile, with less anticholinergic burden but a higher potential for increased blood pressure.

Minkonti should be stored at ambient temperature below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Minkonti is taken orally, usually once daily. The tablet should be swallowed whole with water and can be taken with or without food, unless otherwise directed by the prescribing clinician.

The most serious adverse events to monitor include significant hypertension, acute urinary retention that may lead to obstruction, and rare but severe reactions such as angioedema or QT‑interval prolongation. Patients should seek immediate medical attention if they experience any of these symptoms.

Minkonti is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any of its excipients. Caution is also advised for individuals with a history of urinary retention or those taking medications that strongly affect CYP2D6 or CYP3A4 metabolism.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT